Ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA) is linked to visual impairment, according to 2 case reports published online February 27 in JAMA Ophthalmology. One expert ...
Ocriplasmin (Jetrea®; ThromboGenetics, Inc.; Iselin, New Jersey) recently burst onto the scene to aid in the treatment of vitreomacular adhesion (VMA). Ocriplasmin gained US Food and Drug ...
(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of ...
Please provide your email address to receive an email when new articles are posted on . A single intravitreal injection of ocriplasmin resulted in statistically significant improvement in ...
In two ancillary studies of two multi-center international clinical trials led by the University of Southern California (USC) Eye Institute, the injectable drug ocriplasmin appears to improve vision ...
Please provide your email address to receive an email when new articles are posted on . LISBON, Portugal — Real-life data of a selected, homogeneous group of patients with vitreomacular traction only, ...
In two ancillary studies of two multi-center international clinical trials led by the University of Southern California (USC) Eye Institute, the injectable drug ocriplasmin appears to improve vision ...
To describe a survey of the use of ocriplasmin by members of the British and Eire Association of VitreoRetinal Surgeons (BEAVRS) for VitreoMacular Traction (VMT) and Full Thickness Macular Hole (FTMH) ...
If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical ...
Stalmans et al. (Aug. 16 issue) 1 report that intravitreal injection of ocriplasmin was superior to injection of placebo in altering the vitreoretinal interface of affected eyes. It was associated ...
If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole Leuven, Belgium - 23 December, 2011 - ThromboGenics NV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results